SNDX
NASDAQ HealthcareSyndax Pharmaceuticals, Inc. - Common Stock
Biotechnology
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
�� 市场数据
| 价格 | $24.23 |
|---|---|
| 成交量 | 1,621,769 |
| 市值 | 2.14B |
| 贝塔系数 | 0.410 |
| RSI（14日） | 55.4 |
| 200日均线 | $17.82 |
| 50日均线 | $22.78 |
| 52周最高 | $25.59 |
| 52周最低 | $8.58 |
| Forward P/E | -44.96 |
| Price / Book | 32.79 |
🎯 投资策略评分
SNDX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 💰 Dividend Daddy (47/100) — 此策略 高股息率 + 低波动性.
评分最低的策略： 🎈 Over-Hyped (16/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SNDX in your text
粘贴任何文章、记录或帖子 — 工具将提取 SNDX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.